MA50047A - Administration orale d'analogues peptidiques de glp-1 - Google Patents

Administration orale d'analogues peptidiques de glp-1

Info

Publication number
MA50047A
MA50047A MA050047A MA50047A MA50047A MA 50047 A MA50047 A MA 50047A MA 050047 A MA050047 A MA 050047A MA 50047 A MA50047 A MA 50047A MA 50047 A MA50047 A MA 50047A
Authority
MA
Morocco
Prior art keywords
glp
oral administration
peptidic analogues
peptidic
analogues
Prior art date
Application number
MA050047A
Other languages
English (en)
Inventor
Sergei Pechenov
Janardhanan Anand Subramony
Puneet Tyagi
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MA50047A publication Critical patent/MA50047A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MA050047A 2017-10-31 2018-10-30 Administration orale d'analogues peptidiques de glp-1 MA50047A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762579186P 2017-10-31 2017-10-31

Publications (1)

Publication Number Publication Date
MA50047A true MA50047A (fr) 2020-07-08

Family

ID=66331379

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050047A MA50047A (fr) 2017-10-31 2018-10-30 Administration orale d'analogues peptidiques de glp-1

Country Status (23)

Country Link
US (1) US11173124B2 (fr)
EP (1) EP3703817A4 (fr)
JP (1) JP2021501172A (fr)
KR (1) KR20200081411A (fr)
CN (1) CN111655338A (fr)
AR (1) AR116451A1 (fr)
AU (1) AU2018360382A1 (fr)
BR (1) BR112020008220A2 (fr)
CA (1) CA3079376A1 (fr)
CL (1) CL2020001131A1 (fr)
CO (1) CO2020005485A2 (fr)
CR (1) CR20200185A (fr)
DO (1) DOP2020000082A (fr)
EA (1) EA202091095A1 (fr)
IL (1) IL274096A (fr)
MA (1) MA50047A (fr)
MX (1) MX2020004497A (fr)
PE (1) PE20210116A1 (fr)
PH (1) PH12020551018A1 (fr)
SG (1) SG11202003627PA (fr)
TW (1) TW201932139A (fr)
WO (1) WO2019087083A2 (fr)
ZA (1) ZA202003149B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019087083A2 (fr) 2017-10-31 2019-05-09 Medimmune, Llc Administration orale d'analogues peptidiques de glp-1
FR3120189A1 (fr) * 2021-03-01 2022-09-02 Farid Bennis Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1
KR20230010571A (ko) 2021-07-12 2023-01-19 한미약품 주식회사 Glp-1 유사체를 함유하는 경구 투여 제형 조성물
WO2023065231A1 (fr) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Administration orale d'agents thérapeutiques
WO2023161792A1 (fr) * 2022-02-22 2023-08-31 Astrazeneca Ab Formulations de caprate de sodium compressible

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556837A (en) * 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
GB0308734D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
EP2679270B1 (fr) 2011-02-24 2016-11-09 Hisamitsu Pharmaceutical Co., Inc. Composition d'analogue de glp-1 pour des dispositifs de micro aiguille
EP2844269A4 (fr) * 2012-03-28 2016-01-06 Amylin Pharmaceuticals Llc Administration transmuqueuse de polypeptides génétiquement modifiés
BR112015026325A2 (pt) * 2013-05-02 2017-07-25 Novo Nordisk As dosagem oral de compostos glp-1
US20160106814A1 (en) 2013-05-30 2016-04-21 Novo Nordisk A/S Novel Oral Pharmaceutical Composition for Treatment of Diabetes
TWI726889B (zh) * 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
CN106366166A (zh) * 2016-08-30 2017-02-01 苏州普罗达生物科技有限公司 脑源性神经营养因子促进剂多肽及应用
WO2019087083A2 (fr) 2017-10-31 2019-05-09 Medimmune, Llc Administration orale d'analogues peptidiques de glp-1

Also Published As

Publication number Publication date
DOP2020000082A (es) 2020-08-31
SG11202003627PA (en) 2020-05-28
AR116451A1 (es) 2021-05-12
PE20210116A1 (es) 2021-01-19
KR20200081411A (ko) 2020-07-07
PH12020551018A1 (en) 2021-05-31
AU2018360382A1 (en) 2020-06-18
BR112020008220A2 (pt) 2020-10-27
WO2019087083A3 (fr) 2019-08-08
US11173124B2 (en) 2021-11-16
JP2021501172A (ja) 2021-01-14
CL2020001131A1 (es) 2020-10-23
CA3079376A1 (fr) 2019-05-09
WO2019087083A2 (fr) 2019-05-09
EP3703817A4 (fr) 2021-08-18
MX2020004497A (es) 2020-08-13
EA202091095A1 (ru) 2020-09-18
EP3703817A2 (fr) 2020-09-09
US20200323782A1 (en) 2020-10-15
ZA202003149B (en) 2021-06-30
CN111655338A (zh) 2020-09-11
IL274096A (en) 2020-06-30
TW201932139A (zh) 2019-08-16
CO2020005485A2 (es) 2020-05-15
CR20200185A (es) 2020-06-19

Similar Documents

Publication Publication Date Title
MA50047A (fr) Administration orale d'analogues peptidiques de glp-1
MA56006A (fr) Formulations sous-cutanées d'anticorps her2
HK1247822A1 (zh) 用於活性劑口服給藥的製劑
MA51617A (fr) Mécanisme d'administration de médicament
MA46180A (fr) Analogues de l'amyline
MA52249A (fr) Antagonistes de l'intégrine humaine (alpha4) (beta7)
DK3244878T3 (da) Faste orale sammensætningsformer
IL264880A (en) Preparations for oral administration of active substances
MA41159A (fr) Octréotide destiné à être administré par voie orale en association avec d'autres agents thérapeutiques
MA52019A (fr) Schéma posologique de modulateur d'assemblage de capside
DK3551181T3 (da) Behandling omfattende oral eller gastrisk indgivelse af edaravone
DK3762009T3 (da) Toxin-afledte indgivelseskonstrukter til oral indgivelse
DK3886813T3 (da) Farmaceutiske formuleringer af cyclosporinanaloger
PL3793609T3 (pl) Preparat w postaci doustnego roztworu
IL283593A (en) Bernaflam oral preparations
IL282343A (en) soluble medicinal compounds
DK3886820T3 (da) Kapselformuleringer
MA54289A (fr) Analogues deutérés d'acétyl-leucine
EP3880171C0 (fr) Formulation pharmaceutique orale contenant de l'ibuprofène
TR201918833A2 (tr) Pedi̇atri̇k oral enjektör
IL271658A (en) New oral formulations of belinostat
JP1642785S (ja) 子供用いす
MA51199A (fr) Agents d'imagerie
UA38939S (uk) Велобіг-мотоцикл дитячий
UA36633S (uk) Каблучка складена «світлість гідність краса»